HomeWebcastPatent Protection for Pharma and Biotechnology in 2016
Patent Protection for Pharma and Biotechnology CLE CLE

Patent Protection for Pharma and Biotechnology in 2016

Live Webcast Date: Monday, April 18, 2016 from 3:00 pm to 5:00 pm (ET)
Legal (CLE)Recording

Patent Protection for Pharma and Biotechnology CLE

The biotechnology industry is a dynamic sector that creates stable jobs and opens opportunities for economic growth in many different countries, particularly in America. Without a robust and strongly enforceable patent protection, investment in biotech innovation may decrease.

Ironically, though, in 2015, the biotech sector has seen an erosion of patent rights due to Supreme Court decisions. Despite this and other threats to both biotech and pharmaceutical patents, companies are turning for help in dealing with the increasing number of patent validity challenges and post-grant review proceedings.

In this overly-competitive patent landscape, protecting pharmaceutical and biotechnology innovation demands for effective strategies.

In this two-hour Webcast, The Knowledge Group has assembled a panel of key thought leaders that will help pharma and biotech companies understand the critical issues on Patent Protection for Pharma and Biotechnology. They will also offer best strategies and practices with regards to this significant topic.

In this Webcast, the speakers will discuss:

  • Notable Supreme Court Decisions Affecting Pharma and Biotech Industry
    • Mayo Collaborative Servs. v. Prometheus Labs., Inc.
    • Molecular Pathology v. Myriad Genetics
    • Limelight Networks, Inc v. Akamai Technologies, Inc.
  • Patent Protection Challenges Post Mayo, Myriad and Limelight
  • Best Strategies on Protecting Patent for Pharma and Biotech Innovation
  • Up-to-date Legislative Trends on Pharma and Biotech Patents

Agenda

Dr. Douglas J. Bucklin, Attorney-at-Law, 
Volpe and Koenig, P.C.

  • Section 101 Standards for Compositions;
  • Proposed Solutions for Composition Claims;
  • Miscellaneous Topics of Concern to the Industries (e.g., Markush Group Rejections, Ownership)

Dr. Fang Xie, Of Counsel, 
Greenberg Traurig, LLP

  • Recent case law on 101 patent eligibility in the natural law/diagnostic methods category;
  • Practice tips in drafting diagnostic method claims and overcoming 101 rejections

Dr. Dean L. Fanelli, Founding Partner,
Fanelli Haag PLLC

  • Discussion on divided infringement under Limelight v. Akamai.
  • Practice tips on enforcing diagnostic method claims where joint infringement issues arise.

Who Should Attend

  • Biotech/BioPharma Industry Lawyers
  • Biotech/Pharma/Healthcare Attorneys & Advisors
  • Patent Attorneys
  • Patent Licensing Attorneys
  • Pharmaceutical Company Executives
  • Professionals coming from Biotech and Biopharmaceutical Firms
  • Other Related and Interested Professionals 

Patent Protection for Pharma and Biotechnology CLE

Dr. Douglas J. Bucklin, Attorney-at-Law, 
Volpe and Koenig, P.C.

  • Section 101 Standards for Compositions;
  • Proposed Solutions for Composition Claims;
  • Miscellaneous Topics of Concern to the Industries (e.g., Markush Group Rejections, Ownership)

Dr. Fang Xie, Of Counsel, 
Greenberg Traurig, LLP

  • Recent case law on 101 patent eligibility in the natural law/diagnostic methods category;
  • Practice tips in drafting diagnostic method claims and overcoming 101 rejections

Dr. Dean L. Fanelli, Founding Partner,
Fanelli Haag PLLC

  • Discussion on divided infringement under Limelight v. Akamai.
  • Practice tips on enforcing diagnostic method claims where joint infringement issues arise.

Patent Protection for Pharma and Biotechnology CLE

Patent Protection for Pharma and Biotechnology CLE

Dr. Fang XieOf CounselGreenberg Traurig, LLP

Fang Xie, Ph.D., is of counsel in Greenberg Traurig, LLP’s Boson office where she focuses her practice on developing, evaluating, and enforcing intellectual property rights. She has broad experience in worldwide patent and trademark portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, patent infringement and validity analyses, freedom to operate evaluations, as well as intellectual property litigation and pre-litigation counseling. Dr. Xie’s primary technical areas include biotechnology, synthetic biology, and pharmaceuticals, with a focus on nucleic acid synthesis, protein and organism engineering, antibody and biologics/biosimilars, stem cell technology, regenerative medicine, biomarkers, genetic diagnostics, small molecule drugs, analytical chemistry, and cosmetics. She regularly works with clients in the life sciences sector, including biotechnology, pharmaceutical, and chemistry companies, as well as venture capital and institutional investors. 

Patent Protection for Pharma and Biotechnology CLE

Dr. Douglas J. BucklinAttorney-at-LawVolpe and Koenig, P.C.

Doug helps life science clients, with the ultimate goal of helping to deliver the products of science to the people that need them. He helps clients secure and protect their intellectual property, and advises on strategies to avoid or defend themselves against intellectual property owned by others. Doug provides advice regarding due diligence, domestic and foreign patent prosecution, inter-parties matters, reexaminations, litigation,  patentability opinions, infringement opinions and validity opinions. Doug represents a diverse group of clients from individual inventors to companies of all sizes. His clients are primarily involved in life science industries. Doug’s work extends to numerous technology areas including pharmaceuticals, biotechnology, genetics, chemicals, food technology, medical devices and mechanical devices. Previously, Doug worked as a scientist researching structure-function relationships of biomolecules.

Patent Protection for Pharma and Biotechnology CLE

Dr. Dean L. FanelliFounding PartnerFanelli Haag PLLC

Dean L. Fanelli, Ph.D. is a Founding Partner of the Fanelli Haag PLLC whose practice focuses on issues facing the biotechnology, pharmaceutical, and chemical industries.  Dr. Fanelli’s expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, and opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions.  Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as pre-litigation ANDA analyses associated with Hatch-Waxman paragraph IV litigation.  Dr. Fanelli also has expertise with medical products, chemical compounds, polymer compositions, food additives and cosmetic compositions.  Dr. Fanelli gained additional experience in strategic patent management and licensing while working in-house with an international pharmaceutical drug-delivery company and while working with a major consumer product company.


Click Here to Read Additional Material

Patent Protection for Pharma and Biotechnology CLE

Course Level:
   Intermediate

Advance Preparation:
   Print and review course materials

Method Of Presentation:
   On-demand Webcast

Prerequisite:
   NONE

Course Code:
   145286

NASBA Field of Study:
   Business Law

NY Category of CLE Credit:
   Skills

Total Credits:
    2.0 CLE

No Access

You are not logged in. Please or register to the event to gain access to the materials and login instructions.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

Greenberg Traurig, LLP is an international, multi-practice law firm with approximately 1,900 attorneys serving clients from 38 offices in the United States, Latin America, Europe, Asia, and the Middle East. The firm is No. 1 on the 2015 Law360 Most Charitable Firms list, third largest in the U.S. on the 2015 Law360 400, Top 20 on the 2015 Am Law Global 100, and among the 2015 BTI Brand Elite

Website: https://www.gtlaw.com/

Founded in 1987, Volpe and Koenig, P.C. is a full service intellectual property law firm. With over 50 attorneys, patent agents and technical advisors, Volpe and Koenig, P.C. specializes in all areas of technology and  serves a diverse roster of U.S. and global clients. Its team of attorneys and professional staff have advanced technical degrees and experience working within a wide range of industries – including life sciences, computer technology, and electrical components. This blend of expertise in technology and law allows Volpe and Koenig, P.C. to take a proactive approach in its services and strategic advice. Volpe and Koenig, P.C.’s goal is to help its clients better understand the continually changing legal landscape, to offer proactive guidance for protecting intellectual property portfolios, and to provide peace of mind that their intellectual property assets are secure.

Website: https://vklaw.com/

FANELLI Haag PLLC focuses on intellectual property and provides our clients with the highest caliber of legal representation together with the responsiveness, dedication, efficiency and versatility that only a smaller firm can offer.   Our approach is a strategic one.  We are uniquely positioned to provide solutions that not only meet, but anticipate, the needs of our clients. Our seamlessly integrated team of attorneys is able to efficiently partner with our clients to craft comprehensive rationally-designed intellectual property strategies.  Strong scientific backgrounds, as well as years of legal experience working with the United States Patent and Trademark Office, top-tier international law firms and as venture capitalists and in-house counsel, allow our lawyers to work closely with our clients to understand their technical, business, and legal goals.  The Firm provides a range of intellectual property services relating to patent prosecution, pre-investment due diligence investigations, freedom-to-operate analyses, opinion work and IP-sales/licensing transactions.

Website: https://www.fanellihaag.com/

Fang Xie, Ph.D., is of counsel in Greenberg Traurig, LLP’s Boson office where she focuses her practice on developing, evaluating, and enforcing intellectual property rights. She has broad experience in worldwide patent and trademark portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, patent infringement and validity analyses, freedom to operate evaluations, as well as intellectual property litigation and pre-litigation counseling. Dr. Xie’s primary technical areas include biotechnology, synthetic biology, and pharmaceuticals, with a focus on nucleic acid synthesis, protein and organism engineering, antibody and biologics/biosimilars, stem cell technology, regenerative medicine, biomarkers, genetic diagnostics, small molecule drugs, analytical chemistry, and cosmetics. She regularly works with clients in the life sciences sector, including biotechnology, pharmaceutical, and chemistry companies, as well as venture capital and institutional investors. 

Doug helps life science clients, with the ultimate goal of helping to deliver the products of science to the people that need them. He helps clients secure and protect their intellectual property, and advises on strategies to avoid or defend themselves against intellectual property owned by others. Doug provides advice regarding due diligence, domestic and foreign patent prosecution, inter-parties matters, reexaminations, litigation,  patentability opinions, infringement opinions and validity opinions. Doug represents a diverse group of clients from individual inventors to companies of all sizes. His clients are primarily involved in life science industries. Doug’s work extends to numerous technology areas including pharmaceuticals, biotechnology, genetics, chemicals, food technology, medical devices and mechanical devices. Previously, Doug worked as a scientist researching structure-function relationships of biomolecules.

Dean L. Fanelli, Ph.D. is a Founding Partner of the Fanelli Haag PLLC whose practice focuses on issues facing the biotechnology, pharmaceutical, and chemical industries.  Dr. Fanelli’s expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, and opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions.  Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as pre-litigation ANDA analyses associated with Hatch-Waxman paragraph IV litigation.  Dr. Fanelli also has expertise with medical products, chemical compounds, polymer compositions, food additives and cosmetic compositions.  Dr. Fanelli gained additional experience in strategic patent management and licensing while working in-house with an international pharmaceutical drug-delivery company and while working with a major consumer product company.

Ultimate Value Annual Program

Bring a colleague for only $149, a savings of $50 per additional attendee.

  • Unlimited Access to Live & Recorded Webcasts
  • Instant Access to Course Materials
  • And More!

$199